Hormone · Investigational
Relamorelin
No lawful US pathway
01 · Overview
Relamorelin (RM-131) is a synthetic pentapeptide ghrelin receptor agonist that activates the GHS-1a receptor with about sixfold greater potency than native ghrelin and greater plasma stability (PMID 25545036). It stimulates growth hormone release and accelerates gastrointestinal transit.
It was developed mainly for diabetic gastroparesis, and was also studied in chronic constipation (PMID 25545036).
02 · Research summary & key findings
In a phase 2a trial in 204 patients with diabetic gastroparesis, twice-daily relamorelin accelerated gastric emptying and reduced vomiting frequency by about 60 percent versus placebo (Gastroenterology, 2016) (PMID 27055601). In a 12-week phase 2b trial in 393 patients, it reduced core gastroparesis symptoms and accelerated gastric emptying, but the reduction in vomiting was not significant versus placebo and dose-related worsening of glycemic control occurred in 14.5 percent (Gastroenterology, 2017) (PMID 28760384). Phase 3 trials started in 2017 and 2018 are listed as terminated on ClinicalTrials.gov, and it has not been approved.
03 · Regulatory status
Relamorelin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Relamorelin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Hormone
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Relamorelin is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist Neurogastroenterol Motil, 2015. PMID 25545036
- [2]Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis Gastroenterology, 2016. PMID 27055601
- [3]Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study Gastroenterology, 2017. PMID 28760384
Primary literature
- PubMed: "Relamorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Relamorelin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Relamorelin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.